News

Biocodex and THX Pharma (Theranexus) have entered a strategic licensing agreement aimed at advancing treatments for three rare and serious genetic disorders, marking a significant…
Read More...

Everest Medicines has entered an exclusive licensing agreement with Shaanxi Micot Pharmaceutical Technology to commercialize the experimental therapy MT1013 across China and the…
Read More...

Eisai Co., Ltd. and Shanghai Henlius Biotech have signed an exclusive commercialization and co-exclusive development and manufacturing licensing agreement for the anti-PD-1 antibody…
Read More...

Grünenthal and Apotex Inc. have announced a new licensing agreement granting Apotex exclusive rights in Canada to Nebido (testosterone undecanoate), a long-acting injectable therapy…
Read More...

PrimeGen US, a biotechnology company focused on regenerative medicine, has agreed to merge with special purpose acquisition company DT Cloud Star Acquisition Corporation in a…
Read More...

Relay Therapeutics has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational drug zovegalisib in combination with fulvestrant for…
Read More...

Aquestive Therapeutics said the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for its New Drug Application seeking approval of Anaphylm, an…
Read More...

SanegeneBio has entered a global licensing agreement with Genentech, part of the Roche Group, granting the pharmaceutical company exclusive worldwide rights to develop and commercialize…
Read More...

Immix Biopharma, Inc., a clinical-stage biotechnology company focused on developing therapies for difficult-to-treat diseases, has received a major regulatory boost after the U.S. Food…
Read More...

WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and manufacturing of SND006, a novel bispecific antibody being developed…
Read More...

Recordati has entered into a global collaboration and licensing agreement with Moderna to develop and commercialize mRNA-3927, an investigational mRNA-based therapy for the treatment of…
Read More...

IQVIA, a global provider of clinical research services, healthcare intelligence, and commercial insights, has entered into a strategic long-term collaboration with Boehringer Ingelheim…
Read More...

The Lupus Research Alliance has welcomed the U.S. Food and Drug Administration’s decision to grant Breakthrough Therapy designation to litifilimab (BIIB059), an investigational…
Read More...

Sensorion, a clinical-stage biotechnology company focused on developing novel treatments to restore, treat, and prevent hearing loss, has announced a €60 million capital raise to…
Read More...

AstraZeneca has strengthened its weight management and metabolic disease pipeline through a new strategic collaboration with CSPC Pharmaceuticals, targeting the development of multiple…
Read More...

AstraZeneca has announced a landmark $15 billion investment in China through 2030, significantly expanding its research, development, and manufacturing capabilities as part of its…
Read More...

Repertoire® Immune Medicines, a biotechnology company focused on programmable T cell–targeted immune medicines, has entered into a major strategic collaboration with Eli Lilly and…
Read More...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending conditional marketing authorisation for Rezurock…
Read More...

Otsuka Pharmaceutical Development & Commercialization, Inc., together with Otsuka Pharmaceutical Co., Ltd., has reached a key regulatory milestone after the U.S. Food and Drug…
Read More...

Simcere Pharmaceutical Group Ltd. and Boehringer Ingelheim have entered into a global license and collaboration agreement to develop SIM0709, a pre-clinical bispecific antibody designed…
Read More...